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 Introduction 
 In recent years, the phenomenon of illicit opioid use 
has become increasingly diversiﬁ ed in Western societies, 
mainly linked to two developments. First, in several 
countries illicit opioid use commonly involves a rather 
heterogeneous range of opioid drugs: hydromorphone, 
oxycontone, morphine, i.e. typically analgesics diverted 
from medical sources among which, depending on the 
context, heroin may play only a small or no role at all 
 [1–3] . Second, trends from various settings suggest that 
an increasing proportion of illicit opioid users administer 
their drugs by non-injection routes. For example, smok-
ing of heroin has become predominant in many Western 
European drug cultures and snifﬁ ng is the more common-
ly reported non-injection form of heroin use in the US 
 [4–12] . Recent research has shown that illicit opioid use 
in Canada includes a large variety of different opioid 
drugs, with local variance in terms of heroin use  [13] . 
 Evidence from other studies suggests a variety of dif-
ferences in key characteristics between injection and non-
injection opioid users, with the former typically featuring 
higher levels of risk behaviors or harm outcomes. Socio-
demographically, various samples have demonstrated 
that non-injection heroin users are more likely to be 
younger, female and socially stable than injectors  [6, 7, 
12, 14–16] . Several studies have examined the transition 
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dynamics between different routes of administration of 
heroin and related risk factors  [10, 12, 17, 18] . For ex-
ample, Grifﬁ ths et al.  [12] reported that 39% of their sam-
ple of in- and out-of-treatment heroin users in London 
had changed route of administration at least once. There 
is also evidence that the majority of heroin users start off 
with a non-injection way of administration  [10, 17] , 
though heroin snifﬁ ng can also be a long-term route of 
administration  [10] . Grifﬁ ths et al. [12] reported that her-
oin users have clear preferences for their route of admin-
istration. Variability in method of administration has 
been shown to depend on a range of circumstances, in-
cluding (sub-) cultural inﬂ uences  [19] , the types of heroin 
available on the market  [18, 20] and the socio-ecological 
context  [8, 21, 22] . 
Drug use career patterns can vary depending on route 
of opioid administration. Heroin injectors tend to start 
drug use at an earlier age than non-injectors  [12, 23] , who 
typically indicate shorter duration of regular drug use 
 [12, 14–16, 24] . Injectors often indicate more intense 
patterns of drug use, as expressed through higher levels 
of dependence or higher frequency of use  [14, 24–27] , 
and consequently higher drug expenditures  [28] . In terms 
of poly-drug use, heroin non-injectors have been de-
scribed to be less likely to use cocaine or other stimulants 
 [8, 14, 15] , although select studies have found a strong 
relationship between heroin smoking and oral crack use 
 [29] . Injectors also typically report greater lifetime in-
volvement in alcohol and other non-opioid drug use  [23, 
28, 30] .
 Heroin injectors overall appear to be in poorer physi-
cal and mental health than non-injectors. Studies from 
several countries evidence that non-injection users are 
less likely to have been infected with HIV, Hepatitis B 
(HBV) or Hepatitis C (HCV)  [7, 15, 16, 23, 28, 31] . Non-
injection users, however, are still at risk for transmission 
of HIV, HBV or HCV, especially those involved in sex 
work  [32] . Furthermore, risk behaviors related to non-in-
jection forms of substance use (e.g., the sharing of cocaine 
or crack use paraphernalia) have been tentatively associ-
ated with possible HCV transmission  [33–35] . As for 
mental health, Andersen et al.  [23] found a higher preva-
lence of psychiatric disorders in the injector group com-
pared to non-injectors in a prisoner sample. Dinwiddie 
et al.  [30] reported higher rates of antisocial personality 
disorder – but no differences for mood disorders – for 
injectors in comparison to non-injectors in a sample of 
street drug users. 
 Existing data on treatment utilization, although sparse, 
suggest that injectors tend to have increased exposure and 
higher involvement in treatment compared to non-injec-
tors  [15] . For instance, Grifﬁ ths et al.  [12] found that 75% 
of their heroin injector sample and only 37% of current 
non-injectors had been in contact with drug treatment 
programs. In a sample of opiate-dependent detoxiﬁ cation 
inpatients, Andersen et al.  [23] reported that injectors 
were more likely to enroll in treatment programs after 
completion. Finally, evidence on drug users’ experiences 
with the criminal justice system suggests that injectors 
commit more offences, presumably due to a greater need 
for acquisitive crime to cover the expense of more exten-
sive drug use. Stohler et al.  [15] reported that injectors 
had more criminal charges, were more likely to have been 
charged with drug-related offences, and had spent longer 
periods of time in custody. 
 Relatively little attention has been paid to the phe-
nomenon of non-injection opioid use in Canada, where 
the primary focus is typically given to the estimated pop-
ulation of 90,000–125,000 injection drug users  [36, 37] . 
A cohort study of illicit opioid and other drug users in ﬁ ve 
Canadian cities (‘OPICAN’) included both injectors and 
non-injectors, and provided a good opportunity for em-
pirical comparison  [13] . On this basis, the main objective 
of this paper is to explore (a) key differences between cur-
rent injection and non-injection opioid users in the OPI-
CAN cohort, and (b) potential predictors of current injec-
tion status. 
 Methods 
 Sample 
 The present analyses were based on baseline data from the 
 OPICAN cohort study  [13] , a multisite study of illicit opioid users 
from ﬁ ve Canadian cities, namely Edmonton, Montreal, Quebec 
City, Toronto and Vancouver. Eligibility for participation in the 
OPICAN cohort was based on the following criteria: (1) using il-
licit opioids for a minimum of 1 year on the majority of days in the 
week, (2) not having been in a drug treatment program in the pre-
vious 6 months and (3) being at least 18 years old. Participants were 
recruited using community/outreach-based snowball techniques 
such as posters, ﬂ yers, community liaisons and word-of-mouth. Af-
ter eligibility screening, participants were assessed by a standard-
ized multicomponent protocol (see below) uniformly applied across 
the study sites  [38] . Participants provided informed consent and 
were paid a fee. Baseline data were collected between March and 
December 2002, resulting in a total sample of 677 eligible partici-
pants. The study was approved by the local Research Ethics Boards 
in the study sites. 
 Variables 
 Participants’ injection status was the main variable of analysis, 
based on the (‘yes’ or ‘no’) answer to the following two questions: 
‘In the last 30 days, did you inject any drug?’, and ‘Have you ever 
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used needles to inject any drug?’ The ﬁ rst question allowed for the 
differentiation between ‘current injectors’ and ‘current non-injec-
tors’. Among the ‘current non-injectors’, those who had answered 
‘yes’ to the second question were categorized as ‘past injectors’ (i.e., 
individuals who did not inject in the last 30 days but still had a his-
tory of injecting drugs), whereas the rest were categorized as ‘life-
time non-injectors’ (i.e., individuals who never injected drugs in 
their life). 
 All variables included in the bivariate and the subsequent mul-
tivariate analysis were selected on the basis of evidence from the 
literature, and based on self-report data from the interviewer-ad-
ministered study questionnaire, except for HIV and HCV status, 
which were determined by way of salivary antibody testing  [13] . 
Speciﬁ c types of drugs included in the analysis included (all for use 
in last 30 days): heroin, cocaine, crack, alcohol, Valium (benzodi-
azepine), Tylenol (T) 3 or 4 (codeine) and Dilaudid (hydromor-
phone). Evidence from previous analyses had demonstrated the 
association between these drugs and injection status  [39] . Drug use 
frequency was measured by the number of days each drug had been 
used in the last 30 days. Health status was based on participants’ 
self-assessment on a ﬁ ve-point-scale (excellent, very good, good, fair 
and poor); for analysis purposes, the ﬁ rst 3 and the last 2 values 
were collapsed. Both physical health and mental health indicators 
were based on self-report responses to questions asking participants 
whether they had any physical or mental health problems. Illegal 
income referred to income generated by property crime (or other 
crime), drug dealing, or sex work/hustling in the last 30 days. Par-
ticipants’ housing status was categorized into one of three possible 
groups, namely ‘permanent’ (regular house, apartment, room), 
‘transitional’ (rooming house, shelter, temporary room or space) or 
‘street’ (homeless, no ﬁ xed address). All other variables were based 
on standard self-report data. 
 Analysis 
 Due to missing values in the variables examined, the analysis 
sample was reduced to 624 cases. The analyses consisted of two 
parts. First, we assessed bivariate associations between current in-
jection status and the above-described variables. The signiﬁ cance 
of bivariate associations was assessed by    2  statistics for categorical 
variables and t test for continuous variables. The level of signiﬁ -
cance was set at p  ! 0.05. For categorical variable differences be-
tween injecting status, groups were considered signiﬁ cant if the 
adjusted standardized residual was greater than 2.0  [40] . In the 
second part, current injection drug use status (‘yes’ vs. ‘no’) was 
statistically predicted by logistic regression, including only – in line 
with the conceptual theory behind logistic regression – potential 
predictors of this dependent variable suggested by previous re-
search. These included: age, gender, city, housing status, health 
rating, physical and mental health problems, illegal income, and 
use of select drugs. We also tested possible interactions between city 
and speciﬁ c variables in order to examine whether the inﬂ uence of 
these variables on injection status depended on site. The inclusion 
of interaction terms was limited to variables that were marginally 
signiﬁ cant (at the level of p  ! 0.10) in the regression model. We did 
not test for the impact of interactions between drug types and site 
on injection status, since previous analysis had demonstrated the 
existence of highly distinct drug cultures and drug use patterns 
found in each of the study sites  [13] . Given that regression analysis 
simulates the relationship of variables by holding other factors con-
stant, such interaction analysis would have been counterintuitive, 
generating ambiguous results. None of the tested interaction terms 
reached a level of signiﬁ cance, thus the effects of all variables ex-
amined in our analysis were independent of study site. 
 Results 
 Of the present study sample of untreated illicit opioid 
users, 497 (79.6%) reported that they had injected any 
drug in the 30 days before the assessment and were hence 
classiﬁ ed as current injectors, while 127 (20.4%) did not 
report such injecting behavior and were classiﬁ ed as cur-
rent non-injectors. 
 Differences between Current Injectors and Current 
Non-Injectors 
 Current injectors differed from current non-injectors 
on a number of the characteristics examined in the bi-
variate analysis. In terms of socio-demographics, there 
were signiﬁ cant variations between the study sites regard-
ing participants’ current injection status ( table 1 ). While 
in the total sample 4 out of 5 participants were current 
injectors, a signiﬁ cantly lower proportion of current injec-
tors (57%) were found in Toronto, whereas in Vancouver 
(88%) and Quebec City (89%) the proportion of current 
injectors was signiﬁ cantly higher. Housing status was also 
signiﬁ cantly associated with current injection status ( ta-
ble 2 ). In particular, a higher proportion of current injec-
tors (18%) were living on the street compared to non-in-
jectors (5%). No signiﬁ cant difference, however, was 
found for associations with age and gender. 
Table 1. Injection status (current injection vs. current non-injec-
tion) of OPICAN participants, by site and total)
Current
non-injectors
(n = 127)
Current
injectors
(n = 497)
Total
(n = 624)
%
2 square
(d.f.)
Edmonton 12.2 87.8 100.0 58.60 (4)**
Montreal 19.9 80.1 100.0
Quebec City 11.3* 88.8* 100.0
Toronto 43.0* 57.0* 100.0
Vancouver 11.6* 88.4* 100.0
Total 20.4 79.6 100.0
Unless otherwise stated, results are percentages.
* p < 0.05, ** p < 0.001, for adjusted standardized residuals 
>2.0.
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 In terms of health characteristics, current injectors 
were more likely to self-report poor or fair overall health 
(53%) than non-injectors (42%). They also indicated a 
much higher level of HCV infection (59 vs. 31%). Con-
versely, non-injectors were more likely to report mental 
health problems than injectors (43 vs. 28%). No differ-
ences between the two groups were found for reports of 
physical health problems, the prevalence of recent over-
dose experiences and HIV status. There were no differ-
ences between injectors and non-injectors with respect to 
treatment in the past year; however, injectors expressed 
more interest in enrolling in methadone maintenance 
treatment (MMT) than non-injectors (34 vs. 23%). 
 Furthermore, current injectors were more likely to 
have generated income from criminal activities (56 vs. 
43%) and to have been arrested in the past year (34 vs. 
Table 2. Bivariate associations between selected variables and injection status (current injection vs. current non-
injection)
Variables Current
non-injectors
(n = 127)
Current
injectors
(n = 497)
Total
(n = 624)
2 square/t test
(d.f.)
Demographic
Gender, % female 29.1% 33.4% 32.5% 0.84 (1)
Age, years, mean8SD) 36.089.8 34.689.2 34.989.4 1.39 (187.7)
Housing 14.09 (2)**
Permanent 52.8% 43.7% 45.5%
Transitional 42.5% 38.2% 39.1%
Street 4.7%* 18.1%* 15.4%
Health
Health rating (self) 4.71 (1)*
Poor or fair 41.7%* 52.5%* 49.7%
Good or better 58.3%* 47.5%* 50.3%
Physical health problem (self-reported) 69.3% 71.0% 70.7% 0.15 (1)
Mental health problem (self-reported) 42.5%* 27.8%* 30.8% 10.34 (1)**
HIV-positivea 10.1% 16.9% 15.5% 3.06 (1)
HCV-positiveb 31.1% 59.0% 52.9% 25.24 (1)***
Overdose (last 6 months) 16.5% 17.7% 17.5% 0.01 (1)
In treatment (last 12 months) 27.6% 26.4% 26.6% 0.08 (1)
Interested in MMT 22.8%* 34.2%* 31.9% 6.02 (1)*
Crime and Criminal Justice
Illegal income 42.5% 56.3% 53.5% 7.76 (1)**
Arrested (last 12 months) 41.7% 52.1% 50.0% 4.36 (1)*
Detention (last 12 months) 37.8% 43.3% 42.1% 1.24 (1)
Drug use (days last month)
Heroin use 9.5812.6 16.2813.1 14.9813.2 –5.33 (201.2)***
Cocaine use 1.984.9 7.7810.8 6.6810.2 –8.95 (455.1)***
Crack use 8.0811.3 9.7812.4 9.4812.2 –1.53 (211.2)
Dilaudid use 2.386.3 4.789.3 4.288.8 –3.46 (281.5)**
T3, T4 use 8.6811.7 3.588.3 4.589.3 4.70 (159.8)***
Valium use 5.9810.2 3.387.6 3.888.2 2.69 (163.4)**
Alcohol use 8.2810.0 6.689.8 6.989.9 1.60 (622)
* p < 0.05, ** p < 0.01, *** p < 0.001, for adjusted standardized residuals >2.0.
a HIV-positive: n = 517 (i.e., 109 current non-injectors, 408 current injectors); based on salivary antibody 
test.
b HCV-positive: n = 476 (i.e., 103 current non-injectors, 373 current injectors); based on salivary antibody 
test.
MMT = Methadone maintenance treatment.
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23%), yet there was no signiﬁ cant difference between in-
jectors and non-injectors in their exposure to detention 
in the last 12 months (43 vs. 38%). 
 Differences were also found with regards to drug use. 
On the one hand, current injectors reported signiﬁ cantly 
higher numbers of average days of cocaine, heroin and 
Dilaudid use, while the use of T3/T4 tablets as well as 
Valium was signiﬁ cantly more common among non-in-
jectors. No differences were found with regards to crack 
and alcohol use. 
 Data indicating that current non-injectors featured 
relatively high rates of HIV and HCV as well as overdose 
experiences led us to a more differentiated examination 
of this group, in which they were divided into past in-
jectors and lifetime non-injectors for these variables. 
 Table 3 shows the results of this three-group comparison. 
Looking at HCV status, a signiﬁ cant difference between 
lifetime non-injectors and current injectors (5 vs. 59%) 
emerged. Past injectors also had a relatively high HCV 
rate of 47% and thus featured a similar HCV infection 
rate to that of current injectors. With regards to HIV sta-
tus, no signiﬁ cant difference was found between any of 
the three groups, although current injectors had a some-
what higher rate (17%) than the other two groups (about 
10% each). 
 Likewise, there was no difference between the three 
groups in terms of having experienced an overdose in the 
last 6 months. Here again, current injectors were at slight-
ly higher risk (19%) than the other two groups (about 12% 
each). 
 Predictors of Current Injecting Status 
 In the second part of our analyses, we estimated a lo-
gistic regression model in order to assess the independent 
inﬂ uence of speciﬁ c variables on current injection drug 
use status ( table 4 ). In contrast to the bivariate tests, we 
only included variables that we perceived as potential 
predictors of drug injection. The emerging odds ratios 
(ORs) were interpreted as the relative risk of having in-
jected a drug in the month preceding the assessment. 
 For demographic variables, housing status and study 
site emerged as signiﬁ cant predictors. Individuals who 
were living on the street were about 3.5 times more likely 
to be current injectors than those living in permanent 
housing. Those living in transitional housing (e.g., board-
ing house, hostel) were not signiﬁ cantly more at risk of 
current injection compared to the latter group. Partici-
pants living in Edmonton were almost 5 times more like-
ly to be current drug injectors than those living in Van-
couver. Montreal and Toronto users each had about half 
the risk of reporting current injection compared with 
Vancouver study participants; however, we cannot ex-
clude the possibility that these differences were due to 
chance, as they did not produce statistical signiﬁ cance. 
 Among the health-related factors, only mental health 
problems were signiﬁ cantly associated with users’ injec-
tion status. Those reporting such problems were at about 
40% lesser risk of current injecting. 
 In terms of drug use, the frequency of cocaine, heroin 
and Dilaudid use was associated with higher risk of cur-
rent drug injection. Speciﬁ cally, for every 10 days of co-
caine use (per month) the likelihood of injecting almost 
tripled (184% increase). In a similar direction, the odds 
of injecting increased by 79% for every 10 days of heroin 
use and by 63% for every 10 days of Dilaudid use 1 . Par-
ticipants also reporting the use of crack or Valium did not 
feature an increased risk of injecting drugs. 
1
  The odds ratio of 10 days’ use was calculated by raising the respective OR 
to the 10th power; for example, for heroin 1.79 = 1.0610.
Table 3. HIV status, HCV status and overdose by never injectors, past injectors and current injectors
Lifetime non-
injectors (n = 41)
Past injec-
tors (n = 86)
Current injec-
tors (n = 497)
Total
(n = 624)
2 square
(d.f.)
% n % n % n % n
HIV-positivea 10.5 4 9.9 7 16.9 69 15.5 80 3.07 (2)
HCV-positiveb 5.1* 2 46.9 30 59.0* 220 52.9 252 42.19 (2)**
Overdose (last 6 months) 12.2 5 12.2 16 18.6 88 17.7 109 0.89 (2)
* p < 0.05, ** p < 0.001, for adjusted standardized residuals >2.0.
a HIV-positive: n = 517 (38 lifetime non-injectors, 71 past injectors, 408 current injectors).
b HCV-positive: n = 476 (39 lifetime non-injectors, 64 past injectors, 373 current injectors).
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 Finally, users who generated income from illegal 
 sources (property crime, drug dealing or sex work) were 
signiﬁ cantly more likely to be current drug injectors than 
those not involved in such activities. 
 Discussion 
 Our analyses offered an examination of differences be-
tween current injectors and non-injectors in the OPICAN 
cohort, as well as an exploration of possible predictors of 
injection status in this population. First, we observed that 
a sizable minority – about 1 in 5 participants – in the 
OPICAN cohort were current non-injectors. So far, the 
predominant attention has been on injecting drug users 
in the Canadian context, with little focus on non-injec-
tors. Our data documents that – similar to other jurisdic-
tions  [9, 17, 19, 41] – a non-injection population of street 
drug users exists in Canadian cities that warrants distinct 
consideration. Notably, the proportions of non-injectors 
in the study cohort varied considerably between cities, 
with, for example, the rate of non-injectors being about 4 
times higher in Toronto than in Vancouver or Quebec 
City. Other Canadian studies of illicit drug user popula-
tions appear to corroborate these local patterns or differ-
ences, although the possibility for systematic comparison 
is limited due to the local nature of these studies as well 
as the distinct study criteria and foci  [42–45] . Given that 
site also emerged as a predictor of injection status in the 
logistic regression, it is reasonable to assume that socio-
environmental factors, including drug cultures, drug mar-
kets, health or social services and enforcement, may play 
a substantial role in inﬂ uencing injection status. Our data 
limitations regretfully do not allow for further causal 
analyses of these circumstances, yet this should be a top-
ic of future research. 
 Evidently, the population of current injectors from 
this cohort is characterized by a variety of factors that 
render them a population at elevated levels of risks re-
lated to their drug use compared to the current non-injec-
OR 95% CI p
lower upper
Gender, male 0.85 0.50 1.43 0.532
Age 1.02 0.99 1.05 0.316
City (Vancouver) *** 0.000
Edmonton 4.88** 1.72 13.87 0.003
Montreal 0.46 0.19 1.07 0.072
Quebec-City 1.46 0.43 4.96 0.545
Toronto 0.55 0.25 1.21 0.137
Housing (permanent) * 0.041
Transitional 1.24 0.76 2.02 0.396
Street 3.47* 1.31 9.14 0.012
Health rating (poor or fair)
Good or better 0.63 0.39 1.02 0.062
Physical health problema 1.67 0.94 2.94 0.079
Mental health problema 0.60* 0.36 0.99 0.046
Valium, frequency of useb 1.00 0.97 1.03 0.915
T3/T4s, frequency of useb 0.95*** 0.93 0.98 0.000
Cocaine, frequency of useb 1.11*** 1.06 1.16 0.000
Crack, frequency of useb 0.99 0.96 1.02 0.433
Heroin, frequency of useb 1.06*** 1.03 1.08 0.000
Dilaudid, frequency of useb 1.05* 1.01 1.10 0.010
Illegal income, yes 1.18 0.71 1.97 0.518
The reference group is speciﬁ ed in brackets.
a Self-reported problem in the last 12 months.
b Number of days used in the last month.
* p < 0.05, ** p < 0.01, *** p < 0.001 (n = 624)
For variables with more than two categories (e.g. city), level of signiﬁ cance for all cat-
egories combined is indicated in the ﬁ rst row.
Table 4. Logistic regression model of 
‘current injector’ status
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tion group. Compared to current non-injectors, current 
injectors exhibited a higher level of HCV infection, self-
reported worse health status, were more likely to be inad-
equately housed, more likely to generate illegal income 
and to have been arrested in the past year. These social 
and health determinants have been identiﬁ ed in previous 
studies as major predictors of preeminent harms associ-
ated with street drug use and thus reinforce the notion 
that the current injector group in our study is of great 
public health concern  [46–49] . 
 Clearly, there were some indicators where differences 
between the two main comparison groups did not mate-
rialize, contrary to what could have been expected from 
the literature. For example, we found no signiﬁ cant dif-
ferences in average age, recent overdose experiences or 
HIV status between the two groups (although the latter 
was probably due to small numbers). A deeper investiga-
tion triggered by these observations, however, revealed 
that in fact our observed current non-injection group con-
sisted to a large extent of past injectors, i.e., users who 
had been injecting drugs in the past but were not doing 
so currently, versus a smaller number of individuals who 
reported that they had never injected drugs. While the 
never-injection group also demonstrated risk character-
istics for HIV or HCV infection or overdose, this analysis 
highlights the possible phenomenon of switching routes 
of administration in our study sample, as it has also been 
shown in other studies  [5, 8, 9] . In effect, a rather sizable 
proportion of our study sample (14%, n = 86) had shifted 
from injection to non-injection drug use practices at some 
point in their career, transitioning from a risky to a some-
what less risky form of drug use. Additional analyses 
showed that the sub-group of past injectors was signiﬁ -
cantly older than the group who had never injected (data 
not shown), which may underscore the possibility of a 
‘career’ pattern with older drug users ‘maturing out’ of 
their injection practices  [12, 50, 51] . Our data did not al-
low for further analyses on the question of overall dynam-
ics or causes behind this transition phenomenon; how-
ever, future studies ought to focus on this important ques-
tion. 
 Our logistic regression model of current injection sta-
tus documented the primary inﬂ uence of site or environ-
ment (as discussed above) as well as the use of several 
speciﬁ c substances in determining current injection prac-
tices in our sample. Frequency of heroin, cocaine and 
Dilaudid was positively associated with active injection 
status. This relationship can be interpreted in several 
ways. First, users for whom the abovementioned sub-
stances were the primary drugs of choice, the preferred 
route of administration was through injection in order to 
achieve the desired effects. Second, given that the local 
study sites featured distinct drug markets, injection status 
indirectly may have been a function of drug availability 
on local drug markets and their typical routes of admin-
istration (again pointing to the role of site ecology). Third, 
route of administration has also been associated with eco-
nomic dynamics, namely that drug injecting can be the 
result of a desire for the most ‘cost-effective’ use of drugs, 
i.e., to reach maximum effect under the conditions of 
limited means (e.g., high drug prices or limited resources 
for acquisition)  [17, 52] . On the other hand, we observed 
that for a couple of substance types (e.g., Valium, T3/T4), 
use was associated with current non-injecting. These 
overall associations between type of substance used and 
route of administration mirror the ﬁ ndings of a latent 
class analysis with the OPICAN baseline sample, from 
which  distinct ‘injector’ and ‘non-injector’ groups 
emerged as deﬁ ning clusters  [39] . 
 Our analysis offers some key implications for interven-
tions and policy. First, given the elevated risk and harm 
proﬁ le of the current injector group, the main focus of ac-
tive interventions – be it treatment or more pragmatic 
harm reduction efforts – must be targeted toward this 
population on both an individual and a public health lev-
el. Clearly, needle exchange programs are a core element 
of secondary prevention efforts for injectors and have 
been shown effective in reducing injection-related risk 
behaviors  [53, 54] . While needle exchange programs exist 
in all OPICAN study sites and most cities across Canada, 
their utilization remains limited, and numerous studies 
have demonstrated that a much broader approach, rang-
ing from housing or income support to supervised injec-
tion facilities, is required  [55–57] . The feasibility and im-
pact of the latter is currently under exploration in a pilot 
study in Vancouver and discussed in several other Cana-
dian cities  [58] . Given the strong predictive role of hero-
in and cocaine use, the need for more effective treatment 
interventions for these substances is evident. Such pro-
grams must go beyond the current standard of MMT, 
which has a limited rate of acceptance among heroin us-
ers and in many instances even exacerbates the desire for 
cocaine use  [59–61] . Additionally, our study highlights 
the need for prevention effort, speciﬁ cally targeting dif-
ferences in injection status. A speciﬁ c understanding – in 
our case for the Canadian con-text – is required on 
(a) what measures can effectively be applied to prevent 
the (small) group of never injectors from a possible tran-
sition to injection, and (b) what circumstances or inter-
ventions might lead past injectors to change from injec-
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tion to non-injection practices. Given that non-injection 
drug use was associated with reduced health consequenc-
es, including a signiﬁ cantly lower rate of HCV infection 
compared with current injectors (and that past injectors 
would be less likely to spread HCV by way of sharing in-
jection equipment), the potential risk reduction beneﬁ ts 
of these circumstances are evident. As suggested, not 
switching to injecting or changing from injecting to other 
routes of administration appears to be related to a multi-
tude of different factors, including drug availability, eco-
nomics, health risk perceptions, social pressures and edu-
cation, yet only a few studies have explored the possibil-
ity of such targeted interventions  [62–65] . 
 Our study has some limitations. Given that illicit opi-
oid and other drug users are hidden populations, repre-
sentative sampling is not possible  [66] . In addition, re-
cruitment for the OPICAN study did not include criteria 
related to injection status or behavior but focused on spe-
ciﬁ c drug use patterns (i.e., frequency of opioid use). Giv-
en the suggested associations between drug use frequency 
and injection status, our recruitment criteria may have 
artiﬁ cially assembled a study population with an inherent 
bias in terms of participants’ injection status. Hence over-
all, our results clearly do not allow for generalizations to 
other drug use populations but should be viewed speciﬁ -
cally for this population. Our analysis of injection status 
was based on two questions (see above), focusing on in-
jection in the ‘last 30 days’ and ‘ever’. These questions 
did not allow for more sensitive analyses of detailed in-
jection/non-injection patterns, the length of injection his-
tories or the timing of transition from injection to non-
injection that may have been desirable for more in-depth 
analyses. Our study also relied predominantly on self-re-
port data, although the validity of such data from illicit 
drug users has been documented to be reliable and of high 
quality  [67, 68] . Finally, given that we have used a cross-
sectional study design, we are not able to investigate dy-
namics of causality. 
 Clearly, non-injection drug use and its associated char-
acteristics are part of illicit opioid and other drug use 
populations in Canadian cities. Given the speciﬁ c risks 
and harms associated with active injection and the poten-
tial lessons that can be learned from non-injectors, a more 
systematic examination is warranted. 
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Announcement
 The European Working Group on Treatment of Alcohol Dependence (EWGTAD) 
will be meeting in Warsaw on October 16–17, 2006. Themes of debate include: treatment 
of psychiatric co-morbidity, social environment involvement, research on physical co-
morbidity.
Registration is free. A limited number of new participants is welcome. For more details 
contact: Secretariat EWGTAD, Ms Sabine Bruyere, bruyere@api.or.at.
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